Clinical trials located in

Brno

Brno city is located in Czechia. Currently, 20 clinical trials are being conducted in this city.

Brno, the second-largest city in Czechia, serves as the administrative center of the South Moravian Region. Founded around the year 1000, it boasts a rich history, evident in its medieval Spilberk Castle and the iconic Cathedral of St. Peter and Paul. The city is also renowned for its modernist architecture, including the UNESCO-listed Villa Tugendhat by Mies van der Rohe. Brno is a hub for education and culture, hosting numerous universities, theaters, and museums. Its unique blend of historical and contemporary influences makes it a dynamic urban center.

  • CT-EU-00119838

    Study on the effectiveness and safety of M281 in adults with warm Autoimmune Hemolytic Anemia

    The study focuses on Warm Autoimmune Hemolytic Anemia (wAIHA), a condition where the immune system mistakenly destroys red blood cells. This leads to symptoms like fatigue, weakness, and jaundice (yellowing of the skin or eyes). The trial examines the effects of a therapy named M281 (Nipocalimab). The purpose of the study is to evaluate the efficacy and safety of M281. Patients participating in the study will receive either M281 or a placebo. It aims to compare improvements in health and monitor any side effects.

    The study structure is as follows:

    Double-blind period: This lasts for 24 weeks, where participants will be randomly assigned to one of three groups. One group will receive M281 every 4 weeks, alternating with a placebo every 4 weeks. Another group will receive M281 every 2 weeks, and the third group will receive a placebo every 2 weeks.

    Open-label extension period: This phase extends for 144 weeks, where all participants will receive M281, either every 2 weeks or every 4 weeks.

    Participants will be monitored for 8 weeks after the last dose to check for any ongoing effects of the treatment. The study aims to provide comprehensive information about the effectiveness and safety of M281 in treating wAIHA.

    • M281
    • placebo
  • Baricitinib study in children with juvenile idiopathic arthritis

    This clinical trial is designed to test whether Baricitinib is safe and effective in the treatment of systemic juvenile idiopathic arthritis in children aged 1 to 18 years. Participants will be assigned to one of two groups. In the first group, some participants will receive Baricitinib and others Tocilizumab as the reference drug. In the second group, all participants will receive Baricitinib.

    The primary objective of the study is to evaluate the percentage of participants who experience at least a 30% improvement in disease symptoms after 12 weeks of treatment according to the modified American College of Rheumatology Pediatric Response Criteria (PediACR30). Baricitinib is administered orally and Tocilizumab is administered by subcutaneous injection.

    • Tocilizumab
    • baricitinib
  • Study of a new drug for moderate to severe Rotator Cuff Tendinopathy

    The clinical trial examines the use of secukinumab, a drug, for treating moderate to severe rotator cuff tendinopathy—a shoulder condition characterized by pain and limited movement. The study explores whether secukinumab can improve symptoms and physical function compared to a placebo. Participants will receive either the drug or placebo in addition to standard care, under a randomized, double-blind, and placebo-controlled setup, to ensure the results are unbiased.

    • placebo
    • Secukinumab
  • Extended safety study for participants using spartalizumab alone or combined

    This study relates to a type of medication called spartalizumab. The goal is to find out if this medicine, when given alone or with other treatments, is safe and doesn’t cause any unwanted side effects. The study is open to people who have already been involved in past studies for spartalizumab. The reason for this is to keep giving these people access to the treatment while also continuously assessing its safety.

    • spartalizumab/PDR001
  • Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    • aflibercept
    • OPT-302
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab
  • Testing a new combination therapy with acalabrutinib for a specific type of lymphoma

    This clinical trial is investigating a new combination therapy for diffuse large B-cell lymphoma, a type of lymphoma. The treatment combines Acalabrutinib, a targeted therapy drug, with R-CHOP, a chemotherapy mix consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, a standard chemotherapy regimen. The aim of the study is to evaluate the safety and effectiveness of this combination in improving patient outcomes. It focuses on patients who have not been previously treated for lymphoma. The study aims to find better treatment strategies for this particular type of lymphoma.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Acalabrutinib
    • Cyclophosphamide
    • Rituximab
  • Study on the efficacy of pirtobrutinib for mantle cell lymphoma

    This clinical trial is designed for patients diagnosed with mantle cell lymphoma (MCL), a type of blood cancer. The primary objective of the study is to assess the efficacy of a new drug called pirtobrutinib in comparison to other similar drugs that have received approval from the U.S. Food and Drug Administration (FDA). Participants may be involved in the study for a duration of two years or more, contingent on their condition not worsening. The trial will categorize patients into two groups: one receiving pirtobrutinib, and the other receiving either ibrutinib, acalabrutinib, or zanubrutinib, which are existing FDA-approved drugs for this condition. Throughout the study, the participants’ health condition, symptoms, and any side effects will be closely monitored. Additionally, the effectiveness of the treatments will be measured by evaluating the eventual survival rates of the patients.

    • Pirtobrutinib/LOXO-305
    • Zanubrutinib
    • Ibrutinib
    • Acalabrutinib
  • Safety study of tafasitamab with lenalidomide for Diffuse Large B-Cell Lymphoma patients

    In this study, a novel approach to the treatment of Diffuse Large B-Cell Lymphoma (DLBCL) is being investigated. This type of cancer may have either recurred or not responded to previous treatments. The experimental intervention involves the use of two drugs: Tafasitamab, administered intravenously, and Lenalidomide, a oral medication. The study is focused on individuals who have undergone one to three prior treatments and are currently ineligible for intensive chemotherapy or a stem-cell transplant. The study is conducted in an open format, providing transparency regarding the substances being tested. Regular monitoring will be implemented to detect any potential issues and assess the concentration of the medications in participants’ blood.

    • Tafasitamab
    • Lenalidomide
  • Exploring treatment options for newly diagnosed Multiple Myeloma

    This clinical trial investigates two treatment paths for newly diagnosed multiple myeloma patients who are not planned for stem cell transplant initially. The first group receives a combination of bortezomib, lenalidomide, and dexamethasone (VRd) followed by cilta-cel, an innovative therapy. The second group receives VRd followed by continued treatment with lenalidomide and dexamethasone (Rd). The study evaluates the effectiveness of these treatments by monitoring disease progression, treatment response, and patient survival rates. It also assesses the safety and side effects of the treatments, aiming to improve the quality of life and outcomes for patients with multiple myeloma. The trial’s objective is to provide valuable data on the potential benefits of integrating cilta-cel in the treatment regimen, compared to the more traditional approach, offering insights for better management of this challenging cancer.

    • Cilta-cel
    • Fludarabine
    • Lenalidomide
    • Dexamethasone
    • Cyclophosphamide
    • Bortezomib
  • Study of new drug ARV-471 (PF-07850327) and fulvestrant in patients with advanced breast cancer

    The study looks at advanced breast cancer that has spread to other parts of the body (metastasizes). It is aimed at patients with ER+/HER2- breast cancer, which means that the cancer responds to estrogen (a hormone) and does not have excessive amounts of the HER2 protein. The study will compare two drugs: ARV-471 (PF-07850327, vepdegestrant) and fulvestrant.

    Fulvestrant is a drug already used to treat breast cancer, while ARV-471 is a new drug. The aim of this study is to determine whether ARV-471 is safe and effective compared to fulvestrant in patients with advanced breast cancer that cannot be cured by surgery or radiotherapy.

    The study is open to adults with breast cancer recurrence or metastases that cannot be fully cured by surgery or radiotherapy. Candidates should have a confirmed diagnosis of ER+/HER2- breast cancer and previous treatment with CDK4/6 inhibitors combined with hormonal therapy. Patients must not have active brain metastases or liver, kidney or bone marrow failure.

    Treatment continues until the cancer gets worse or the side effects become too severe. Clinic meetings take place approximately every 4 weeks.

    • Vepdegrestrant/ARV-471
    • Fulvestrant
  • Evaluation of Bemarituzumab in patients with solid tumors overexpressing the FGFR2b receptor

    The study concerns patients with solid tumors that are characterized by excessive expression of the FGFR2b receptor (Fibroblast Growth Factor Receptor 2b). In particular, this includes cancers such as head and neck squamous cell carcinoma, triple negative breast cancer, intrahepatic cholangiocarcinoma, lung adenocarcinoma, epithelial ovarian cancer, endometrial adenocarcinoma and cervical cancer. The therapy that will be used in this study is bemarituzumab (also known as AMG 552), administered by intravenous infusion.

    The aim of the study is to assess the safety and tolerability of bemarituzumab and its preliminary anticancer effectiveness. Patients with the above cancers whose disease recurs or does not respond to standard therapies may be eligible to participate in the study.

    Patients must have confirmed recurrent or refractory cancer that is not suitable for surgical treatment. An additional condition is excessive expression of the FGFR2b receptor in their tumor. The experimental therapy includes two phases: in the first phase, determining the optimal dose, and in the second, expanding the therapy to a larger group of patients using a previously determined dose.

    • Bemarituzumab
  • Testing safety and effects of telisotuzumab and docetaxel in Lung Cancer patients

    This study is for adults who have been treated before for a type of lung cancer called non-small cell lung cancer (NSCLC). The aim is to see if a new drug, called telisotuzumab vedotin, works better and is as safe as a common drug called docetaxel. In this study, cancer activity and any side-effects will be observed closely. The treatment will be given by a drip into a vein.The researchers will randomly decide whether each participant will get telisotuzumab vedotin or docetaxel, with an equal chance of getting either drug. While in the study, each person will have regular hospital or clinic visits to check how they are doing with tests and questionnaires.

    • Telisotuzumab Vedotin
    • Docetaxel
  • Study of Tucatinib, Trastuzumab and Pertuzumab in the treatment of HER2+ metastatic breast cancer

    The study is aimed at patients with HER2-positive breast cancer whose disease has spread locally, i.e. close to where it started, and cannot be surgically removed, or has spread to other parts of the body. Treatment in this study includes a combination of drugs: tucatinib (also known as TUKYSA, ONT-380, ARRY-380), trastuzumab (Herceptin, Herceptin Hylecta), and pertuzumab (Perjeta). Some patients will receive a placebo instead of tucatinib.

    All patients will receive trastuzumab and pertuzumab, plus either tucatinib or placebo. Trastuzumab is administered intravenously (IV) or subcutaneously, and pertuzumab is administered intravenously. In some cases, trastuzumab and pertuzumab may be administered subcutaneously in combination.

    The aim of the study is to check whether tucatinib in combination with trastuzumab and pertuzumab works better than placebo. This will also check what side effects may occur while taking this drug combination. Side effects are any adverse effects a drug may have on the body in addition to treating the disease.

    The study includes patients who have already undergone 4-8 cycles of pre-treatment with trastuzumab, pertuzumab and taxane as first-line treatment for advanced breast cancer, and do not show disease progression after completion of this pre-therapy. Patients can have both positive and negative hormone receptor status.

    • Pertuzumab
    • Tucatinib
    • Trastuzumab
  • Comparing favezelimab/pembrolizumab combo with standard chemotherapy for Hodgkin lymphoma

    This study is investigating a treatment for PD-(L)1-refractory, relapsed, or refractory classical Hodgkin lymphoma, a type of blood cancer. Researchers are evaluating a new drug combination known as MK-4280A (favezelimab/pembrolizumab) alongside standard drugs typically used for this condition (bendamustine or gemcitabine). The aim is to determine if MK-4280A is superior to the standard drugs in extending patients’ lifespan and slowing down disease progression. Additionally, scientists will assess the safety and tolerability of MK-4280A during the study, noting any potential side effects of the drug.

    • Favezelimab
    • Pembrolizumab
    • Bendamustine
    • Gemcitabine
  • Evaluating effects of pembrolizumab with chemotherapy and radiation for esophageal cancer

    This trial explores the impact of a drug called pembrolizumab on patients with a specific kind of cancer, Esophageal Carcinoma. It compares two treatments. Some patients will receive the standard treatment (chemotherapy and radiation), plus a placebo. Others will receive the standard treatment (chemotherapy and radiation) plus Pembrolizumab. The reason for doing it is to see if Pembrolizumab, when added to normal treatment, can help patients live without their cancer getting worse, or live longer overall. During the trial, patients will either be given pembrolizumab or placebo, as well as one of two chemotherapy combinations and radiation treatment, for about a year.

    • Pembrolizumab
    • levoleucovorin
    • leucovorin
    • 5-Fluorouracil
    • Cisplatin
    • Oxaliplatin
  • To study the efficacy and safety of Alpelisib and Fulvestrant in patients with advanced breast cancer after prior treatment

    The study is aimed at patients with advanced breast cancer, which is hormone-dependent (HR+) and HER2-negative, which means that cancer cells develop under the influence of hormones and at the same time do not have a large number of HER2 receptors. Patients must have a mutation in the PIK3CA gene and progressive cancer after previous therapy with CDK4/6 inhibitors and aromatase inhibitors.

    The study will use two drugs: Alpelisib, administered in the form of tablets, and Fulvestrant, administered as intramuscular injections. Both of these therapies will be compared with placebo in combination with fulvestrant. The aim of the study is to evaluate the effectiveness and safety of combined treatment with alpelisib and fulvestrant compared to placebo plus fulvestrant.

    • Alpelisib
    • Fulvestrant
  • Testing Nipocalimab’s effect on adults with Muscle Weakness

    This study is about a new drug called nipocalimab for patients with a disease called Myasthenia Gravis (MG). MG patients feel weak in their muscles, and nipocalimab potentially could help to lessen this weakness. The drug functions by attaching itself to certain components of the blood to lessen the reaction causing muscle weakness. This large-scale study will take place in multiple hospitals and is organized in different phases including initial checks (4 weeks), treatment (24 weeks) and follow-ups (up to 2 years). It will be measured how well the treatment works through daily activity scores and strength tests.

    • Nipocalimab
  • Comparing treatments in multiple myeloma: talquetamab in combination with other medication

    This study aims to explore the combined effects of talquetamab, daratumumab, pomalidomide, and dexamethasone for treating relapsed or refractory multiple myeloma. One group of patients will receive talquetamab subcutaneous in combination with daratumumab and pomalidomide. The second group will receive talquetamab subcutaneous in combination with daratumumab. The patients of the third group will be treated with daratumumab subcutaneous in combination with pomalidomide and dexamethasone. The research is divided into three phases: screening, treatment, and post-treatment follow-up. The study will assess efficacy, safety, and monitoring various health indicators at specific time points. The results of this combination therapy will be compared to choose the safest and the most effective treatment. The overall duration of the study is expected to be up to 6 years and 6 months.

    • Pomalidomide
    • Talquetamab
    • Dexamethasone
    • Daratumumab
  • Comparing tarlatamab and standard therapy in recurring small cell lung cancer

    The study is a trial comparing tarlatamab, a new therapy, with standard care for Small Cell Lung Cancer (SCLC) patients who’ve had platinum-based chemotherapy. It aims to improve survival rates and assesses the drug’s safety and effectiveness in about 700 people. Participants will either receive tarlatamab or standard treatments like lurbinectedin, topotecan, or amrubicin. The main goal is to see if tarlatamab can extend patients’ lives compared to usual treatments. The study also monitors health-related quality of life, treatment response, and safety.

    • Amrubicin
    • Tarlatamab
    • topotecan
    • Lurbinectedin

See more clinical trials in other cities in Czechia:

.